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Abstract

Chemotherapy is a common method of cancer treatment, and cisplatin is a common
anticancer compound used in chemotherapy. While effective, cisplatin is known to cause many
side effects, and people can form resistance to it. Because of these problems, new
chemotherapeutic compounds are needed. One compound that has shown anticancer properties,
an ability to overcome resistance, and nontoxicity is ruthenium. Multiple mono-ruthenium
compounds have been previously studied and were found to be effective. The current research
project synthesized a diruthenium compound Cp2Ru2(bipy)2(DMSO)2 and exposed the
compound to human liver cells (HepG2) to determine cytotoxicity. Increasing concentrations,
between 5 and 50 μM, of the compound were tested, in addition to the solvent DMSO (control).
Cytotoxicity effects were evaluated at 24, 48, and 72 hour time points. The results showed that
Cp2Ru2(bipy)2(DMSO)2 produced significant decreases in cell growth at 10 μM concentrations
and was more effective at the 24 hour time point when compared to cisplatin, however, 15 μM
cisplatin was more effective at 48 and 72 hour time points. Additionally, there were solvent
effects with DMSO at higher concentrations of the diruthenium compound (25 and 50 μM). At
low concentrations, solvent did not show an effect.

Introduction

Cancer is a disease that will affect almost 40% of people in their lifetime. There are over
100 types of cancer, with the most common types being breast, prostate, lung, and colon
(National Cancer Institute, 2015). As of 2015, there are 454.8/100,000 new cases of cancer with
171.2/100,000 deaths from cancer each year. There are over 13.7 million people in the United
States living with cancer (National Cancer Institute, 2015). Because of the prevalence of cancer,
finding new treatments has been an important goal of many researchers. One common method of
cancer treatment is chemotherapy, which is the use of medications to destroy cancer cells in the
body. Many of these compounds target cancer cells but can also affect nearby normal cells. Thus,
chemotherapy can cause many side effects and decrease a person’s quality of life due to the
many side effects. People can also develop resistance to chemotherapy, making the treatment not
effective for them. Because of these concerns, safer and more effective forms of chemotherapy
need to be discovered.
Ruthenium has been shown to have anticancer properties, nontoxic, and able to overcome
resistance (Bergamo et al., 2012). We wanted to synthesize a compound with a two ruthenium
centers and compare it to cisplatin, a popular chemotherapeutic drug. The goal of this research is
to determine how well this novel diruthenium compound is able to decrease cell growth to
compare to cisplatin.
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Literature Review
Cancer
Cancer is characterized by uncontrolled cell division that spreads into surrounding
tissues. In a healthy individual, cells divide, form new cells, and die when appropriate. In a
patient with cancer, cells may not die when they are supposed to and new cells grow when not
needed (National Cancer Institute, 2015). Cells that divide without stopping can form tumors,
and cancerous tumors that form are called malignant tumors.
Cancer is caused by genetic changes in an individual. Mutations occur in the DNA of
cancer patients, and the changes may be a cause or a result of the cancer. Genetic changes can
be inherited from parents or caused by DNA damage from environmental factors including
smoking and ultraviolet radiation (Greenblatt et al., 1994). There are many types of cancer that
are characterized by where they are located in the body.
Chemotherapy
Chemotherapy is a common method of treatment for cancer. Chemotherapy uses
pharmaceutical medications to destroy cancer cells in the human body. One group of medications
used in chemotherapy can target cell division (Payne and Miles, 2008). Cancer cells are known
to divide more than normal cells, but chemotherapy is not specific to cancer cells and can target
any dividing cell in the body. Since chemotherapy can target any dividing cell, it affects other
rapidly dividing cells including hair, nails, and bone marrow (Payne and Miles, 2008).
Most types of chemotherapy damage the genetic material in a cell to cause cell death
(Payne and Miles, 2008). There are four types of cellular activities that cause cell death:
apoptosis, necrosis, autophagy, and mitotic catastrophe (Ricci and Zong, 2006). Apoptosis and
autophagy are types of programmed cell death, which means there is genetic control over the
2

processes. Programmed cell death involves absorption of cellular components by nearby cells
and is used by healthy cells to maintain normal tissues (Ricci and Zong, 2006). Necrosis and
mitotic catastrophe are typically thought of as accidental cell death which are caused by either
physical damage to the cell or abnormal cellular division. These are characterized by
dysregulation of the signaling pathways that control cell death. The various types of
chemotherapy have been shown to induce all types of cell death (Ricci and Zong, 2006).
Although it can be an effective method of cancer treatment, chemotherapy has
downsides. It can damage DNA in normal cells leading to cell death, causing many side-effects
Payne and Miles, 2008). Side effects can include but are not limited to nausea, vomiting, hair
loss, constipation, shaking, and diarrhea (Boer-Dennert et al., 1997). Also, some people are
resistant to forms of chemotherapy. For some, chemotherapy does not improve the status of the
cancer and may not be effective.
Cisplatin
Cisplatin, developed in 1965 and approved by the Food and Drug Administration (FDA)
in 1978, is classified as an alkylating agent and used for a variety of cancers including testicular,
ovarian, bladder, esophageal, breast, cervical, stomach and prostate.
Side effects of cisplatin occur in greater than 30% of the patients receiving the
medication. These include nausea, vomiting, kidney toxicity, blood test abnormalities, low white
blood cell count, and low red blood cell count. Women who are pregnant are informed of the
potential risks of cisplatin on a developing fetus. Cisplatin is a pregnancy category D drug,
which means there is risk of harm to an unborn baby but the risks may outweigh the benefits for
the mother (U.S. Department of Health and Human Services, 2015). It is recommended for
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patients who are undergoing chemotherapy with cisplatin to take anti-nausea medications, eat
small amounts of food regularly, maintain regular fluid intake, wash hands often, avoid sun
exposure, and get plenty of rest.
Since cisplatin is classified as an alkylating agent, it is most active in the resting phase of
the cell and is cell cycle non-specific (Larsen, 2013). An alkylating agent is a type of anticancer
drug that inhibits transcription of DNA into RNA by substituting alkyl groups for hydrogen on
DNA, which causes crosslinking in the DNA (National Library of Medicine, 2015). This results
in mutated DNA. Cisplatin is neutral in charge upon entering the cell (Larsen, 2013). Once inside
a cell, cisplatin undergoes hydrolysis, where a chlorine ligand is replaced by a molecule of water
(Larsen, 2013). This creates a positively charged species, as shown in Figure 1.

Figure 1. Cellular uptake of cisplatin (Larsen, 2013)
Once inside the cell, cisplatin has a number of possible targets including DNA, RNA,
sulfur-containing enzymes such as metallothionein and glutathione, and mitochondria.
4

Metallothionein and glutathione have been shown to increase cellular resistance to cisplatin,
making cisplatin less effective (Basu and Krishnamurthy, 2010). The effects on mitochondrial
DNA are not well understood, but it is possible that damage to mitochondrial DNA resulting
from cisplatin treatment contributes to cell death (Larsen, 2013).
A downside to cisplatin use is the resistance that can occur. Once cisplatin interferes with
DNA replication, it activates the cell’s repair mechanisms and undergoes cell death if unable to
repair (Oliver et al., 2010). It has been shown that cells treated with cisplatin alter the DNA
repair pathways, allowing them to become resistant to cisplatin (Oliver et al., 2010). Research
shows that tumor suppressor gene p53 can become mutated, resulting in a higher chance of
resistance to cisplatin. Another downside of cisplatin is the many side effects that can occur, as
previously described. Because of these issues with cisplatin, other drugs are being developed
and tested for anticancer abilities, including ruthenium compounds.
Ruthenium
Ruthenium, atomic number of 44, was discovered in 1840 by Karl Karlovich Klaus after
he extracted, purified, and confirmed the new metal (RSC, 2015). Ruthenium has many uses in
the electrical and chemical industries and is an alloying agent when combined with metals such
as platinum and palladium (Seddon and Seddon, 1984). Ruthenium is considered highly toxic
and carcinogenic.
Work with ruthenium as an anticancer drug began between 1975 and 1985 and lead to a
few important findings that include: the hypothesis of “activation by reduction”, the
transportation of ruthenium to cancer cells by transferrin, and DNA binding different from
platinum drugs (Bergamo and Sava, 2011). Ruthenium is of interest to researchers because it is
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believed to be less toxic and more capable of overcoming resistance when compared to cisplatin
(Bergamo and Sava, 2011). This seems to occur by the transportation of ruthenium to the tumor
cells by transferrin and the selective activation to more reactive species by the reducing
environment of tumors when compared to healthy tissues (Bergamo and Sava, 2011). Ruthenium
anti-cancer medications are designed to mimic cisplatin, particularly for targeting DNA,
although they may alter DNA differently (Bergamo and Sava, 2011).
While there are similarities, ruthenium-based complexes have been shown to act
differently from cisplatin in that ruthenium accumulates in neoplastic masses rather than healthy
tissue, and then can lead to cellular apoptosis (Antonarakis and Emadi, 2010). Additionally,
ruthenium remains inactive until it reaches the tumor. With many tumors being resistant to
cisplatin, this allows ruthenium to perhaps attack tumors that would normally be more resistant
to chemotherapy and radiation (Antonarakis and Emadi, 2010). Ruthenium shows an ability to
fight metastasis in addition to the primary tumor by interfering with type IV collagenolytic
activity to reduce metastasis (Antonarakis and Emadi, 2010).
Research has been conducted with mono-ruthenium compounds as chemotherapeutic and
diagnostic agents. Previous research has shown that ruthenium can be used as an antiinflammatory agent, antibiotic, antidiabetic agent, antioxidant, and anti-analgesic agent among
other uses (Naik et al., 2015). Two mono-ruthenium compounds have been clinically tested,
NAMI-A and KP1019. KP1019 mimicked cisplatin and had potential to overcome resistance
and possibly systemic toxicity because of its different mode of action on the nucleic acid
(Bergamo et al., 2012). KP1019 also showed some cancer stabilization in patients and a phase II
study with colorectal cancer patients is being planned (Antonarakis and Emadi, 2010). NAMI-A
showed an ability to act on tumor metastasis (Bergamo et al., 2012). NAMI-A appears to
6

interfere with type IV collagenolytic activity to reduce the metastatic potential, instead of
binding to DNA (Naik et al., 2015). The structures of the two compounds are shown below in
Figure 2.

Figure 2. Structures of NAMI-A and KP2019 (Gianferrara et al., 2009)
Current research project
The current research project seeks to evaluate if a diruthenium compound is cytotoxic to
human liver cells (HepG2). Since mono-ruthenium compounds have been shown to have anticancer properties, the goal was to analyze how effective a diruthenium compound that was
synthesized in the laboratory was in producing cell death. First, a diruthenium compound
(Cp2Ru2(bipy)2(DMSO)2) was synthesized and exposed to target cells. Our goal was to evaluate
the toxicity of the compound on target cells and to compare those results with cisplatin, a known
and effective chemotherapeutic drug. (Figure 3).
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Figure 3. Structure of Cp2Ru2(bipy)2(DMSO)2
Our hypothesis was that the diruthenium compound would be more toxic than cisplatin.
The goal of the project was to provide insight into the potential chemotherapeutic activity that
diruthenium compounds can have as anti-cancer agents. We determined the concentrations at
which these compounds can produce at least 50% cytotoxicity, and determined their
effectiveness compared to the very commonly used drug cisplatin. The hope is that the current
project can lead to further research with diruthenium or other ruthenium compounds.

Methods
Chemical synthesis of Ruthenium compound
Silver triflate, naphthalene, and the starting material Cp2Ru2(CO)4(Br)2 were used to
synthesize a new compound in the nitrogen glove box. Acetonitrile was added to solubilize the
materials, and the solution was microwaved for 20 minutes at 180o C. After microwaving, the
mixture was transferred into diethyl ether where the insoluble material was separated by
filtration. The filtration was followed by a methylene chloride wash. The compound was then
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dried, rinsed with tetrahydrofuran (THF), rinsed with diethyl ether once again, and vacuum dried
at room temperature.
The next day, acetonitrile was added to the compound, (Cp2Ru2Np), and the solution was
photolyzed (visible light) for 3 hours. NMR spectral analysis was performed following the 3
hour period to determine if the reaction was complete. Half of the compound (yellow liquid) was
evaporated by the vacuum and bipyridine was added. The solution was microwaved for 20
minutes at 80o C. The solution changed from a yellow color to dark red. Lithium chloride (LiCl)
was added to the dark red mixture, and the mixture was microwaved again for 20 minutes at 80o
C. The mixture was left stirring on a stir plate overnight.
Finally, the compound [Cp2Ru2(bipy)2(Cl)][OTf] was evaporated to produce a dark
powder (bipy is 2,2'-Bipyridine). The compound was dissolved in DMSO, which released the
chloro ligand thereby producing Cp2Ru2(bipy)2(DMSO)2.

Cp2Ru2(bipy)2(DMSO)2 Solution
3.5 mg of Cp2Ru2(bipy)2(DMSO)2was dissolved in 1 mL of DMSO to create a working
test solution that was used to treat cells.
Cell culture
The HepG2 cell line, a non-tumorigenic human hepatocellular carcinoma, was used. The
cell cultures were maintained in a humidified incubator at 37C with 5% CO2. They were grown
in Eagle’s Minimum Essential Medium (EMEM) supplemented with 10% fetal bovine serum
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(FBS), and 1% penicillin/streptomycin. Cells were subdivided (split) when the dish was 80-85%
confluent or full using trypsin digestion.
Cell Treatment for MTT proliferation assay
On day 1, HepG2 cells were plated in medium containing 10% fetal bovine serum and
1% penicillin/streptomycin. For each experiment, 10,000 cells/well were plated in 96-well plates.
On the 2nd day, old medium was removed and replaced with medium containing
increasing concentrations of Cp2Ru2(bipy)2(DMSO)2. The concentrations ranged from 5-100 μM.
DMSO solvent controls were used as comparison for each concentration. The positive control
was 15 μM Cisplatin and the same volume of NaCl was also used as the solvent control
comparison. On days 3, 4, and 5, 24, 48, and 72 hour MTT cell proliferation assays were
performed.
MTT Cell Proliferation Assay
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay is a
colorimetric assay that assesses cell viability. MTT is a yellow colored compound but turns into
a purple formazan salt when reduced by mitochondrial enzymes of viable cells only. A MTT
assay kit (ATCC) was used initially. Ten L of 5 mg/mL MTT reagent was added to each well,
followed by the plate being incubated for 2 hours until purple formazan appeared. One hundred
L of SDS stock solution (10% Sodium Dodecyl Sulfate in 0.01 N HCL) was added per well and
the plate was incubated in the dark for an additional two hours. Absorbance was measured at 570
nm on a spectrophotometer. After 4 weeks, MTT compound (Sigma) was purchased separately
and dissolved in phosphate buffered saline (5 mg/mL). The same stop solution was used. For the
MTT assay, 20 μL of MTT solution (5 mg/mL) was added to each well and plates were
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incubated for 4 hours at 37o C. One hundred μL of stop solution was added and the plate was
incubated overnight at 37o C with plates being read (570 nm) on the spectrophotometer for
determination of the absorbance of each sample the following morning.
Data Analysis
Data analysis using statistical software (SPSS) to determine the average amount of
decrease in cell proliferation for each concentration at each time point was conducted. Three 24
hour experiments, four 48 hour, and three 72 hour experiments were analyzed with 8 replicates
for each concentration. One Way ANOVA with Bonferroni post-hoc analysis was used to
determine statistical significance where p<0.05 was considered statistically significant. To
compare how treated cells behaved compared to control (untreated cells) a ratio of the
absorbance of treated cells divided by the absorbance of the control cells was calculated.
Results
Synthesis of Cp2Ru2(bipy)2(DMSO)2
After the synthesis of the compound shown in Figure 3, it was assumed that the chlorine
ligand became unbound from the ruthenium metal centers and that DMSO was bound to the
metal centers instead. The compound was used for comparison against cisplatin in MTT cell
proliferation assays.
MTT Cell Proliferation Analysis
Following MTT cell proliferation assays, the concentrations of 5, 10, 25, and 50 μM of
Cp2Ru2(bipy)2(DMSO)2 were compared to DMSO solvent control counterparts. Cisplatin (15
μM) was used as the positive control and its solvent NaCl was also included. Figure 4 shows
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the results following 24 hours of exposure to HepG2 cells. The 10 μM concentration decreased
cell growth by 15%, 25 μM by 22%, and 50 μM by 24%; all of these concentrations showed a
statistically significant decrease in cell growth compared to control. Concentrations of DMSO
did not decrease cell growth while the cisplatin control decreased cell growth by 2% NaCl did
not.

*

*

*

Figure 4. At 24 hours, 10 μM Cp2Ru2(bipy)2(DMSO)2 on HepG2 cells showed 15% decrease in
cell growth. Cp2Ru2(bipy)2(DMSO)2 showed a statistically significant change (*) from control
with p < 0.05 at 10, 25, and 50 μM.
Following a 48 hour exposure of Cp2Ru2(bipy)2(DMSO)2 to HepG2 cells, cell growth was
assessed by comparing increasing concentrations of compound to similar volumes of the DMSO
solvent control, and the positive control. Five μM of the compound decreased cell growth by
15%, 10 μM decreased growth by 19%, 25 μM decreased growth by 37%, while 50 μM
12

decreased cell growth by 50%. Cp2Ru2(bipy)2(DMSO)2 after a 48 hour exposure showed a
significant change from control with all the concentrations tested. However, DMSO alone also
25%. Cisplatin also showed a significant change from control, decreasing cell growth 37% while
its solvent control did not (Figure 5).

*

*

*

*
*

*
*

Figure 5. At 48 hours, 5 μM Cp2Ru2(bipy)2(DMSO)2 on HepG2 cells showed 15% decrease in
cell growth. Cp2Ru2(bipy)2(DMSO)2 showed a significant change (*) from control with p < 0.05
at 5, 10, 25, and 50 μM. DMSO showed a significant change from control with p < 0.05 at 25
and 50 μM. Cisplatin also showed a significant change from control.

Following exposure of Cp2Ru2(bipy)2(DMSO)2 for 72 hours to HepG2 cells, cell growth
was assessed by comparing increasing concentrations of compound to similar volumes of the
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DMSO solvent control, and the positive control. So, after 72 hour exposure, the concentration of
5 μM deceased cell growth by 10%, 10 μM decreased growth by 15%, 25 μM decreased growth
by 36%, and 50 μM decreased growth by 58%; all the concentrations were statistically
significant in decreasing cell growth compared to control cells. However, DMSO showed a
significant change from control with p < 0.05 at the higher concentrations, 25 and 50 μM,
decreasing cell growth by 22% and 43%. Cisplatin also showed a significant change from
control, decreasing cell growth 88% while the solvent NaCl was not significant from control.

*

*
*
*
*
*

*

Figure 6. At 72 hours, 5 uM Cp2Ru2(bipy)2(DMSO)2 on HepG2 cells showed 10% decrease in
cell growth. Cp2Ru2(bipy)2(DMSO)2 showed a significant change (*) from control with p < 0.05
at 5, 10, 25, and 50 μM. DMSO showed a significant change from control with p < 0.05 at 25
and 50 μM. Cisplatin also showed a significant change from control.
14

Discussion
In the search for new compounds with anticancer properties, diruthenium compound
Cp2Ru2(bipy)2(DMSO)2 was synthesized and tested against a known positive control, cisplatin, a
common compound used in chemotherapy. Cisplatin can cause many side effects in patients, and
patients can develop primary or secondary resistance to the compound, creating a need for new
anticancer compounds. We wanted to know how Cp2Ru2(bipy)2(DMSO)2 compared to cisplatin
in terms of cytotoxicity.
The results from the MTT analysis of HepG2 cells showed that only 10 μM of
Cp2Ru2(bipy)2(DMSO)2 was needed to produce a significant decrease in cell growth after 24
hours (Figure 4). However, only 5 μM of compound was needed to produce a significant
decrease in cell growth after 48 and 72 hours, as shown in Figure 5 and Figure 6. At these
concentrations, there was no solvent effect seen with DMSO alone.
Cisplatin (15 μM) was used as a positive control for all time points. It did not
significantly affect cell growth at 24 hours, but was significant at both 48 and 72 hours. Cisplatin
showed the greatest decrease in cell growth at the 72 hour time point by decreasing cell growth
by 85% while the diruthenium compound decreased growth by 60% at 50 μM after 72 hours,
however, for the compound, there was a solvent effect at this concentration, thus we cannot
assume the effect was due only to the compound but it may also be due to the solvent. At lower
concentrations of compound, there was no such solvent effect; it was only seen at higher
concentrations at longer time points. These results indicate that Cp2Ru2(bipy)2(DMSO)2 can
produce significant decreases in cell growth at low concentrations and that it was more effective
at the 24 hour time point when compared to cisplatin, however, 15 μM cisplatin is more effective
at longer time points. It is unknown if the diruthenium compound achieved greater cell death
15

than a mono-ruthenium compound because there was not a mono-ruthenium compound tested to
compare to.
Future steps of this research could include determining the mechanism of cell death the
cells undergo when exposed to Cp2Ru2(bipy)2(DMSO)2, whether it be apoptosis or necrosis. It
could also include developing alternate synthesis methodologies that would allow the solubility
of diruthenium compounds in aqueous solvents. Finally, Cp2Ru2(bipy)2(DMSO)2 could be
evaluated for potential toxicity in tumorigenic cell lines.
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